Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071996
Filing Date
2025-05-15
Accepted
2025-05-15 07:41:51
Documents
67
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q pyxs-20250331.htm   iXBRL 10-Q 2038841
2 EX-10.1 pyxs-ex10_1.htm EX-10.1 49022
3 EX-31.1 pyxs-ex31_1.htm EX-31.1 16454
4 EX-31.2 pyxs-ex31_2.htm EX-31.2 16436
5 EX-32.1 pyxs-ex32_1.htm EX-32.1 9923
6 EX-32.2 pyxs-ex32_2.htm EX-32.2 9191
7 GRAPHIC img33342731_0.jpg GRAPHIC 664529
  Complete submission text file 0000950170-25-071996.txt   9665916

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pyxs-20250331.xsd EX-101.SCH 1355201
69 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20250331_htm.xml XML 1135851
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40881 | Film No.: 25948744
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)